Medivation Inc. (MDVN): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Medivation ( MDVN) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.8%. By the end of trading, Medivation fell 59 cents (-1.1%) to $54.28 on light volume. Throughout the day, 688,412 shares of Medivation exchanged hands as compared to its average daily volume of 966,600 shares. The stock ranged in price between $53.70-$54.80 after having opened the day at $54.80 as compared to the previous trading day's close of $54.87. Other companies within the Health Care sector that declined today were: Ventrus Biosciences ( VTUS), down 22.9%, Halozyme Therapeutics ( HALO), down 11.7%, Theratechnologies ( THER), down 10.3%, and Rockwell Medical ( RMTI), down 9.9%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Medivation, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for the treatment of serious diseases in the United States and Europe. Medivation has a market cap of $4.23 billion and is part of the drugs industry. Shares are up 11.2% year to date as of the close of trading on Tuesday. Currently there are eight analysts that rate Medivation a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Medivation as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including poor profit margins, generally higher debt management risk and feeble growth in the company's earnings per share.

On the positive front, ARCA biopharma ( ABIO), up 72.8%, Hemispherx Biopharma ( HEB), up 21.9%, ADVENTRX Pharmaceuticals ( ANX), up 21.3%, and BioClinica ( BIOC), up 19.4%, were all gainers within the health care sector with Boston Scientific ( BSX) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Medivation Founder Takes Helm at Axovant, Shares Spike

Second-Quarter Picks and Pans

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors